SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 51.59-1.1%Dec 2 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: IRWIN JAMES FRANKEL who wrote (2416)12/28/2000 10:22:34 PM
From: Biomaven  Read Replies (1) of 52153
 
IJ,

I recall that AZN returned rights to this drug last year or so, which means it can't be a blockbuster. Haven't followed them since then - I see now that Shire picked up the rights outside the US.

Here's a description of the drug:

centerwatch.com

The dose that people have to take is huge - 6.75 grams/day. Wonder if that might limit its utility?

OTOH, a pretty small market cap for an approved drug. Any GI types around that might comment on this drug?

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News